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ABSTRACT
The HOX and PBX gene families encode transcription factors that have key roles 
in establishing the identity of cells and tissues in early development. Over the last 20 
years it has become apparent that they are also dysregulated in a wide range of solid 
and haematological malignancies and have a predominantly pro-oncogenic function. 
A key mode of transcriptional regulation by HOX and PBX proteins is through their 
interaction as a heterodimer or larger complex that enhances their binding affinity and 
specificity for DNA, and there is growing evidence that this interaction is a potential 
therapeutic target in malignancies that include prostate, breast, renal, ovarian 
and lung cancer, melanoma, myeloma, and acute myeloid leukaemia. This review 
summarizes the roles of HOX and PBX genes in cancer and assesses the therapeutic 
potential of HOX/PBX dimer inhibition, including the availability of biomarkers for its 
application in precision medicine.
HOX GENES IN CANCER
The HOX genes
The HOX genes are a family of homeodomain-
containing transcription factors that were originally 
identified due to their pivotal roles in early development 
[1]. These are reflected in a range of striking 
developmental changes in HOX-mutant animals, most 
notably Drosophila. One of the best known examples of 
this is the ectopic expression of the Antennapedia (Antp) 
gene in cells that would normally give rise to antennae; a 
near perfect pair of legs replaces the antennae of adult flies 
that develop from these embryos [2]. These observations 
revealed that HOX genes can determine the identity 
of cells and tissues, and hence also help regulate the 
proliferation, differentiation, and survival of these cells. 
The identification of additional mutants revealed a family 
of 8 HOX genes in the fly, which are expressed in an 
anterior to posterior pattern along the main embryonic axis 
and specify the identity of different embryonic structures 
[1].
An unusual feature of HOX gene organization is 
their existence in clusters within a single chromosome, 
and 2 further rounds of duplication in the course of 
vertebrate evolution have given rise to 4 chromosomal 
clusters in mammals, referred to as A, B, C, and D. The 
cluster names are also used to denote specific genes in 
conjunction with the position of the gene in the cluster, 
thus for example HOXD1 is the most 3’ member of the 
D cluster [3]. The genes within clusters share enhancer 
regions and this plays a significant role in the regulation 
of HOX gene expression, as do a number of microRNAs 
encoded within each cluster [4]. A further unusual feature 
of HOX regulation, which is in part enabled by enhancer 
sharing, is temporal and spatial collinearity during 
development, whereby each HOX gene in a cluster is 
expressed earlier in development and with a more anterior 
border of expression than its 5’ neighbour [1]. 
In total mammals have 39 HOX genes that play key 
roles in patterning both the main embryonic anterior to 
posterior axis at a very early stage of development and 
embryonic structures that develop later, for example 
the limbs and many of the organs [3]. The high level of 
sequence identity between HOX genes is reflected in a 
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high level of functional redundancy during development 
[5], although there are also many examples of HOX genes 
playing specific roles in the embryo, for example during 
limb development where members of the HOXD cluster 
define specific structures [6].
Although HOX genes were originally characterized 
as developmental genes they also play a number of 
important roles in the adult, and indeed their original 
embryonic expression patterns are sometimes maintained, 
at least to a limited extent [7]. The most notable examples 
of HOX gene function in the adult include the maintenance 
of hematopoietic stem cells (HSCs) [8], the specification 
of different blood cell lineages [9], and regulation of 
tissue identity during implantation and the menstrual 
cycle [10]. In addition, and as discussed in detail below, 
the HOX genes become highly dysregulated (and 
often over expressed) in a wide range of both solid and 
haematological cancers.
HOX cofactors
Although HOX proteins can bind to DNA through 
their homeodomain, this binding is relatively non-specific 
as it generally involves only a 4 base pair recognition 
sequence. Greater specificity is conferred by the binding 
of cofactors such Pre-B-cell Leukemia Homeobox 
(PBX) and Myeloid Ecotropic Viral Integration Site 1 
Homolog (MEIS) proteins [11]. The latter bind to HOX 
proteins 9-13 [12], whilst PBX family members bind to 
HOX proteins 1-11 [13-15]. In addition to increasing 
the complexity of the DNA binding sequence, these 
cofactors also influence key transcriptional events 
such as the recruitment of RNA polymerase II or III, or 
transcriptional inhibitors such as HDAC. Hence, for 
example, HOXC6 can recruit RNA polymerase II through 
a TAAT site in the promoter of the S100B gene to promote 
its transcription in neuroblastoma cell lines [16], whilst 
HOXD3 needs to bind as a heterodimer with PBX1B to 
recruit RNA polymerase II and activate transcription of the 
ITGB3 gene (encoding Integrin β3) during angiogenesis 
[17]. Conversely, HOXB6 and HOXD4 can bind to and 
inhibit the histone acetyl transferase CBP on the TWIST1 
enhancer, thereby repressing TWIST1 transcription [18].
In addition to determining target gene specificity 
and the mode of transcriptional regulation, HOX cofactors 
also play a role in post-translational regulation through 
facilitating the entry of HOX proteins into the nucleus 
(considered in more detail below).
The role of HOX genes in cancer
A potential role for HOX genes in cancer 
first became apparent from their frequent inclusion 
in chimeric, oncogenic gene fusions that drive the 
formation of haematological malignancies [9]. It has 
subsequently become apparent that HOX genes are 
profoundly dysregulated in a wide range of both solid and 
haematological malignancies, most frequently showing 
very high levels of over expression. There is now a vast 
amount of data available on HOX gene expression in 
different malignancies, and it is not within the scope of 
this review to detail this. The reader is instead referred 
to a number of recent specialist reviews that examine 
the expression and possible function of HOX genes in 
specific cancer types such as melanoma [19], and head 
and neck [4], prostate [20], breast [21], ovarian [22], and 
pancreatic cancer [23]. Despite the very high degree of 
HOX dysregulation in cancer, relatively few HOX genes 
have been shown to act as oncogenes in the strictest 
sense, i.e. that their forced expression in phenotypically 
normal cells is sufficient to cause a switch to a malignant 
phenotype, although an important example is HOXA9, 
which can immortalize normal bone marrow cells in 
mice when overexpressed [24]. Current evidence broadly 
indicates that other HOX genes have a general supportive 
role in malignancy, both at the cellular level (for example 
in promoting proliferation and blocking apoptosis) [25], 
and at the tumour level, where they have been shown to 
variously induce angiogenesis [26], drive metastasis [27], 
and facilitate drug [21, 28, 29] and radiation resistance 
[30]. These pro-oncogenic roles are reflected in numerous 
reports of elevated HOX expression being associated with 
a poor clinical outcome and prognosis (considered in more 
detail below). 
In addition to a pro-oncogenic role, a number of 
HOX genes also act as tumour suppressors. Examples 
include HOXA4, the expression of which can block the 
spread of ovarian cancer cells [31], HOXA5 that has 
been shown to stabilize the P53 protein in breast cancer 
cells [32] and promote an epithelial phenotype [33], 
and HOXC8 which is inversely related to progression 
in ovarian cancer [31]. Intriguingly it seems that the 
regulation of HOX tumour suppressor targets may involve 
HOX binding to the promoter or enhancer region without 
PBX, as the identified binding sites are often for HOX 
only [33, 34], or the HOX protein might have an additional 
function independent of that as a transcription factor [35].
HOX genes as biomarkers
The differential expression of HOX genes in cancer 
make the products of these genes potential biomarkers for 
both diagnosis and prognosis, and for precision medicine 
applications such as predicting treatment response 
(reviewed by Morgan and El-Tanani, 2016 [36]). One of 
the best characterized examples is Engrailed-2 (EN2), a 
gene that is very closely related to the HOX genes but 
which is not located within the 4 main chromosomal 
clusters described above [37]. EN2 is overexpressed 
in a number of different malignancies, most notably 
prostate and bladder cancer, and urinary EN2 protein has 
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been shown to be a potential diagnostic marker of both 
of these diseases [38, 39]. In addition, HOXC6 RNA 
has been shown to be a potential diagnostic marker for 
prostate cancer as part of a multi gene panel [40]. HOX 
gene expression at the RNA level has also been shown to 
have prognostic significance in acute myeloid leukaemia 
(AML) [41], and in several solid malignancies including 
mesothelioma (HOXB4) [42], breast cancer (HOXB7) 
[43], ovarian cancer [44], oral squamous cell carcinoma 
(HOXD13) [45], thyroid cancer (HOXC10) [46], clear 
cell renal cell carcinoma (HOXC11) [47], gastric cancer 
(HOXC6) [48], and bladder cancer (HOXB13) [49]. 
Discreet patterns of HOX gene expression apparently 
exist within different types of cancer, indicating that they 
could be used to distinguish between cancer types when 
the primary tumour type is unknown, for example in 
circulating tumour cells (CTCs) [36].
PBX GENES IN CANCER
The PBX genes
PBX genes are homologues of the Drosophila 
extradenticle gene (Exd) and 4 are encoded in the 
human genome (PBX1-4). Like the HOX genes they 
encode homeodomain-containing transcription factors, 
but do not exist in chromosomal clusters. In addition to 
the homeodomain, PBX proteins contain other highly 
conserved regions, one of which is required for binding 
to a number of closely related transcription factors, MEIS 
and PREP [11]. PBX proteins also include 2 nuclear 
localization signals (NLSs) in the homeodomain region 
and a distinct nuclear export sequence (NES) [50]. 
The extent of nuclear localization of PBX proteins is 
determined by the balance between import and export 
pathways mediated by the NLSs and NES, respectively 
[51]. Unusually, the NES of PBX does not bind to exportin 
to directly promote nuclear exportation, but instead blocks 
access to the NLSs through binding to the homeodomain 
[52].
PBX proteins form strong complexes with HOX1-
11 proteins in the presence of a HOX/PBX DNA binding 
consensus [53-55]. X-ray crystallography data for 
HOXB1-PBX1 and HOXB9-PBX1 complexes on DNA 
have revealed that each of the homeodomains binds to 
one half of an octameric consensus sequence, and that 
this interaction is stabilized by a HOX/PBX interaction 
mediated by a conserved hexapeptide sequenced in HOX 
proteins [15, 56-58]. Full length PBX1 alone cannot 
activate transcription, while a portion of it (amino acids 
39-232) can specifically block transcriptional activation 
by the SP1 transcription factor [59, 60]. However, 
when complexed with HOXB1, PBX1 switches from a 
transcriptional repressor to a transcriptional activator [61]. 
The role of PBX  genes in cancer
Although less studied than the HOX genes in the 
context of cancer, the PBX gene family is known to have 
a number of oncogenic functions. Best characterised of 
these is as a chimeric fusion partner in various leukaemias 
and lymphomas, for example PBX1 and E2A in pre-B 
cell acute lymphoblastic leukaemia [62]. It has also 
been shown that the upregulation of PBX3 together with 
MEIS1 is necessary to drive leukemogenesis efficiently in 
mouse models; PBX3 protein is required both to stabilize 
MEIS1 and induce transcription of the MEIS1 gene [63]. 
Correspondingly, a 4-gene signature consisting of PBX3, 
HOXA7, HOXA9, and HOXA11 has been shown to be an 
independent predictor of poor survival in patients with 
cytogenetically abnormal AML (CA-AML), and that 
PBX3 (but not PBX1 or PBX2) is frequently co-expressed 
with HOXA9 in various subtypes of CA-AML, particularly 
MLL-rearranged AML, and may thus be a potential 
pathologic cofactor of HOXA9. This is further supported 
by the finding that knock-down of PBX3 prevents it from 
exerting a synergistic effect with HOXA9 in promoting 
leukemogenesis [64].
The PBX genes are also over expressed in a number 
of solid tumours. These include colorectal cancer (CRC), 
in which PBX3 expression was shown to be correlated 
with invasive potential in vitro, and significantly 
associated with lymph node invasion, distant metastasis, 
advanced TNM stage and poor overall survival of patients. 
Furthermore, the forced expression of PBX3 in cells with a 
low metastatic potential was shown to promote migration 
and invasion, at least in part through the upregulation 
of phosphorylated extracellular signal-regulated 
kinase (ERK)1/2 [65]. PBX3 has also been shown to 
be upregulated in gastric cancer cells, and that this was 
associated with greater invasion depth, and advanced 
clinical stage and tumour grade. The overexpression of 
PBX3 in gastric cancer cell lines with low endogenous 
PBX3 expression accelerated cell proliferation and 
increased colony formation and cell-invading ability [66]. 
Similarly, increased levels of PBX3 expression have been 
reported in prostate tumours and this was found to have 
prognostic significance in this cancer. PBX3 expression is 
promoted by androgen signalling through a pathway that 
is negatively regulated in part by the Lethal-7 family of 
microRNAs (let-7), which are in turn downstream targets 
of the Myc protoncogene [67]. Although the majority 
of reports implicate PBX3 as the most oncogenic PBX 
gene, a recent study demonstrated that increased PBX1 
expression in ovarian cancer was associated with shorter 
post-chemotherapy survival and increased resistance to 
platinum-based drugs through the maintenance of a stem 
cell-like phenotype [68].
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TARGETING HOX/PBX DIMERS
Strategies for interfering with HOX/PBX dimer 
formation: HXR9 and other peptides
The key roles that HOX and PBX proteins play in 
cancer indicate that they are potential therapeutic targets. 
However, the high level of functional redundancy amongst 
HOX proteins and the general difficulty in producing 
effective small molecule inhibitors against transcription 
factors have proved significant barriers to this approach. 
As an alternative, it was proposed that the interaction 
between HOX and PBX proteins could be targeted, 
as this is mediated by a highly conserved hexapeptide 
sequence in HOX proteins and a hydrophobic binding 
pocket within PBX. Although a small molecule inhibitor 
of this interaction has previously been described, its Kd 
was in the micromolar range and it does not seem to have 
been adopted for experimental or clinical use [69]. To 
date, a more useful set of inhibitors have proved to be 
peptides that employ the hexapeptide sequence to act as 
a competitive antagonist of HOX/PBX binding. Several 
peptides have been described, but the one most frequently 
used is HXR9, an 18 amino acid peptide containing the 
hexapeptide sequence together with 9 arginine residues 
that promote cellular uptake by endocytosis. HXR9 was 
originally shown to be cytotoxic to melanoma cell lines 
and primary melanoma cells and was reported to reduce 
the growth of B16F10 murine melanoma tumours in an 
orthotropic model [25]. Subsequently, HXR9 was shown 
to inhibit the growth of a range of tumour types in mouse 
xenograft models, including non-small cell lung [70], 
breast [34], ovarian [71], and prostate cancer [72], and 
mesothelioma [42], melanoma [73], and meningioma [74] 
(Table 1). 
The mechanism by which HOX/PBX inhibition 
causes cell death remains to be fully elucidated (Figure 1). 
In most solid tumours cell death is mediated by apoptosis 
[25, 34, 42, 71, 72], although in a number of cancers, 
including some types of renal cancer, necrosis instead 
plays an important role [75]. However, both these events 
seem to be activated, at least in part, by a rapid increase 
 Table 1: Previous in vivo studies of HOX/PBX inhibition using HXR9
Cancer (cell line) Delivery (study duration)
Max % 
inhibition of 
tumour growth
Biomarkers investigated Reference
Prostate (LNCaP)
100 mg/kg IT single dose when 
tumour volume > 100 mm3 (52 
days)
530 cFos – tumour response [72]
Breast (SKBR3) 20 mg/kg IT on weeks 1 and 2 (50 days) 340
cFos – tumour response
Mean HOXB1-9 expression – 
sensitivity
[34]
NSCLC (A549)
100 mg/kg IT single dose when 
tumour volume > 100 mm3 (18 
days)
or 10 mg/kg IP twice weekly (18 
days)
880 (IT)
160 (IP)
cFos, EGR1, EGR4 – tumour 
response [70]
Mesothelioma 
(MSTO-211H)
25 mg/kg IP every 4 days, max 5 
doses (37 days) 230
cFos – tumour response
Ratio of mean “tumour suppressor” 
and “oncogenic” HOX expression – 
sensitivity
[42]
Melanoma 
(B16F10)
10 mg/kg IV twice weekly (28 
days) 480
cFos, DUSP1, ATF3 – tumour 
response [25]
Melanoma 
(A375M)
100 mg/kg IT single dose when 
tumour volume > 100 mm3 (21 
days)
440 cFos – tumour response [73]
Ovarian (SKOV-3)
1 × 100 mg/kg IT (week 1) and 
then 10 mg/kg IT twice weekly, 
with or without cisplatin IP 3 
mg/kg weekly (29 days)
140 (300 when 
combined with 
cisplatin)
[44]
Ovarian (SK-
OV3)
1 × 100 mg/kg IV (week 1) and 
then 10 mg/kg IV weekly (32 
days)
200 cFos – tumour response [71]
Meningioma 
(IOMM-Lee)
30 mg/kg IV on days 7, 9, 13, 16, 
19 (21 days) 170 [74]
IT, intratumoral; IP, intraperitoneal; IV, intravenous; NSCLC, non-small cell lung cancer; “tumour response”, actual response 
of tumour to treatment; “sensitivity”, prediction of tumour sensitivity to treatment
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in cFos expression, as preventing this using gene knock 
down strategies can achieve a partial rescue from HXR9-
mediated cell killing [25]. The upregulation of cFos has 
been shown to cause apoptosis in a number of different 
cancers [76-83], in a mechanism that might involve 
activation of Fas ligand (FasL) transcription through the 
AP1 transcriptional activator consisting of the Fos/Jun 
heterodimer, which in turn promotes apoptosis through 
the FasL/Fas receptor pathway [76, 79-82]. High levels 
of cFos tumour expression are associated with longer 
survival in ovarian cancer patients [84], and, in addition 
to promoting apoptosis, it has also been shown to reduce 
the growth of ovarian xenograft tumours in mice through 
changes in cell adhesion [85]. cFos is an early response 
gene to many types of cellular stress, although there is 
now evidence to suggest that HOX/PBX dimers repress 
cFos expression both directly, through HOX/PBX binding 
sites in its promoter, and indirectly through HOX/PBX 
mediated regulation of a cFos-targeting microRNA [73]. 
Predicting sensitivity to HOX/PBX inhibition
As with other types of targeted therapy, companion 
diagnostics are becoming increasingly important 
for patient stratification in clinical trials as well as 
personalized therapies. The identification of markers that 
can predict which tumours will be sensitive to HOX/PBX 
inhibition is an important preclinical goal, although to 
date there is relatively little evidence for a single or even 
multiplex marker that can fill this role outside of limited, 
cancer-specific settings. In a study on breast cancer, the 
sensitivity of breast cancer cell lines to killing by HXR9 
was shown to be strongly associated with the combined 
expression of HOX genes HOXB1 through to HOXB9 
[34]. However, this relationship has not been reported in 
other cancer types, and indeed it was not found amongst 
cell lines derived from mesothelioma, where instead there 
was an apparent relationship between HXR9-mediated 
cell killing and the ratio of expression in HOX genes with 
reported pro-oncogenic functions to those with tumour-
Figure 1: HXR9 mechanisms of action. In the absence of inhibition HOX and PBX dimerize, enter the nucleus, and bind to HOX/
PBX consensus sequences present in numerous target genes. These include cFos, DUSP1, and ATF3, all of which are inhibited by HOX/
PBX dimers. HXR9 mimics the hexapeptide loop of HOX proteins that binds to a pocket in PBX, thereby acting as a competitive inhibitor 
of this interaction. HOX/PBX inhibition greatly increases cFos transcription, and the resulting protein can dimerize with Jun (not shown) 
to activate FasL transcription. FasL protein then binds to the Fas receptor (FasR) and activates the extrinsic apoptotic pathway. The 
transcription of ATF3 and DUSP1 is also enhanced by HXR9. ATF3 stabilizes p53, which in turn promotes mitochondria-mediated 
apoptosis and blocks proliferation, while DUSP1 dephosphorylates MEK and ERK, silencing Ras mediated signalling.
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suppressor functions [42]. Neither of these markers has 
been validated in primary tumours, although in breast 
cancer [34] and mesothelioma [42] a subgroup of primary 
tumours was identified that showed a very high level of 
the combined HOXB1-9 expression and a high HOX 
oncogenic to tumour suppressor ratio, respectively. 
Furthermore, in bone marrow samples from primary AML 
patients, high levels of HOXA gene and PBX3 expression 
were found to be associated with greater sensitivity to 
HXR9 [64].
The lack of a robust and generalized marker of 
tumour sensitivity to HOX/PBX inhibition might be 
related to the difficulty in quantifying these dimers in 
cells and tissues, as opposed to measuring HOX gene 
expression at the RNA or protein level, which is at best an 
indirect measure of this. Work is continuing to develop a 
quantitative assay for HOX/PBX dimers, and it is hoped 
that this will in turn lead to a more accurate test for tumour 
sensitivity to HOX/PBX inhibition.
Biomarkers of response to HOX/PBX inhibition
Surrogate markers of tumour response to treatment, 
which allow an earlier assessment of the efficacy of 
treatment than conventional clinical endpoints (for 
example survival and disease free survival) are of 
growing importance both in clinical trials and in precision 
medicine. The regulatory function of HOX/PBX dimers 
means that there are a number of immediate transcriptional 
targets that change in response to HOX/PBX inhibition. 
These include cFos, as described above, together with 
a number of other targets that might act as a readout of 
the efficacy of inhibitors such as HXR9 [25]. The best 
characterised of these are dual specificity phosphatase 1 
(DUSP1) and activating transcription factor 3 (ATF3). 
DUSP1 can dephosphorylate serine, threonine and 
tyrosine residues in a wide range of substrates, and block 
signalling through the mitogen activated protein kinase 
pathway, thereby preventing cellular proliferation [86], 
and decreased DUSP1 expression is associated with higher 
histological grades in multiple tumour types [87]. ATF3 
also has a potential role in tumour suppression as it can 
stabilize p53 protein and prevent its ubiquination, induce 
apoptosis, and promote cell cycle arrest [88-90]. 
FUTURE DIRECTIONS
There is now considerable in vitro and in vivo 
data supporting the therapeutic potential of inhibiting 
HOX/PBX dimer formation in cancer. To date, however, 
the only effective inhibitors of HOX/PBX binding are 
the HXR9 peptide and its derivatives. Peptide-based 
therapeutics are already used in cancer therapy though 
[91], including Carfilzomib for multiple myeloma [92], 
and indeed a variant of HXR9 for intratumoral injection is 
expected to enter clinical trials during 2018. Developing 
a small molecule inhibitor of HOX/PBX binding remains 
a significant challenge, and the only previously reported 
small molecule inhibitors of this interaction are unlikely to 
have any therapeutic application as the minimum reported 
Kd for PBX binding was 65 µM [69]. Development of 
a small molecule inhibitor therefor remains an important 
clinical goal.
CONCLUSIONS
Since the publication of the initial study in 2007 
it has become increasingly apparent that the HOX/PBX 
dimer is a potential therapeutic target in both solid and 
haematological malignancies. Clinical exploitation of 
this target is aided by the co-development of markers that 
predict the sensitivity of tumours to HOX/PBX inhibitors, 
and which allow the initial response to treatment to be 
monitored. The outcome of clinical trials for peptide 
and small molecule inhibitors of HOX/PBX are eagerly 
awaited.
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